Both wild-type and mutant PUS1 significantly enhanced tumor cell migration compared to controls, and the RNA pseudouridylation levels in the mutant group were similar to controls, indicating that PUS1 primarily functions through a non-enzymatic pathway in prostate cancer cells. Here, PUS1 is linked to prostate cancer.